Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study.

HIV drug resistance antiretroviral therapy genotypic susceptibility score low-level viremia virological suppression

Journal

AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376

Informations de publication

Date de publication:
14 Jul 2023
Historique:
pubmed: 22 6 2023
medline: 22 6 2023
entrez: 22 6 2023
Statut: aheadofprint

Résumé

Despite effective antiretroviral therapies (ARTs), a subset of people living with HIV (PLWH) still experience low-level viremia (LLV, i.e., 50-1,000 copies/mL). The present study compared PLWH experiencing LLV with those maintaining virological suppression (VS) and explored the potential impact of preexisting drug resistance and other factors on LLV. We conducted a retrospective, 1:1 matched case-control study within a cohort of drug-experienced VS subjects from the Italian Antiviral Response Cohort Analysis database, followed in the period 2009-2019. Cases were individuals experiencing LLV, while controls were those who maintained VS. Matching was for calendar year of first ART regimen. Preexisting drug resistance was calculated as cumulative genotypic susceptibility score (GSS) according to regimen administered at the observational period start. To explore the effect of cumulative GSS, treated as a binary variable (≥2 and <2) and other factors on LLV, we performed a logistic regression analysis. Within a main population of 3,455 PLWH, 337 cases were selected. Cases were comparable to the controls for both gender and age. However, cases showed that they had experienced a longer time since HIV diagnosis, a higher number of drugs previously administered, lower baseline CD4

Identifiants

pubmed: 37345697
doi: 10.1089/AID.2023.0015
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Francesca Lombardi (F)

UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Elena Bruzzesi (E)

Infectious Diseases Unit, Università Vita-Salute San Raffaele, Milan, Italy.

Yagai Romeo Bouba (YR)

Chantal BIYA International Reference Center for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.

Domenico Di Carlo (D)

Department of Biomedical and Clinical Sciences "L. Sacco", CRC Pediatric "Romeo and Enrica Invernizzi", University of Milan, Milan, Italy.

Valentino Costabile (V)

Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.

Martina Ranzenigo (M)

Infectious Diseases Unit, Università Vita-Salute San Raffaele, Milan, Italy.

Franco Maggiolo (F)

Department of Infectious Diseases, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.

Antonella Castagna (A)

Infectious Diseases Unit, Università Vita-Salute San Raffaele, Milan, Italy.
Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy.

Anna Paola Callegaro (AP)

Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.

Alessia Zoncada (A)

UO Malattie Infettive, ASST Cremona, Cremona, Italy.

Stefania Paolucci (S)

Molecular Virology Unit, Division of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Valeria Micheli (V)

Laboratory of Clinical Microbiology, Virology, and Bioemergencies, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy.

Silvia Renica (S)

Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.

Antonia Bezencheck (A)

IPRO-InformaPRO S.r.l., Rome, Italy.
EuResist Network GEIE, Rome, Italy.

Barbara Rossetti (B)

Infectious Diseases Unit, AUSL Toscana Sud-Est, Ospedale Misericordia Grosseto, Siena, Italy.

Maria Mercedes Santoro (MM)

Department of Experimental Medicine, University of Rome "Tor Vergata," Rome, Italy.

Classifications MeSH